ACADIA Pharmaceuticals Inc.
NASDAQ:ACADBiotechnology
-$0.13 today
- Market cap
- $3.08B
- Beta
- 0.83
- P/E (TTM)
- 9.7
- EPS (TTM)
- $2.20
Volume 1.89M
Average 1.66M
ACAD Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
ACADIA Pharmaceuticals Inc.NASDAQ: ACAD
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q3 FY2026 selling, general & admin of $159.2M rose 19.3% year over year, behind the +23.5% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 0.7% from the prior quarter. Over 3 fiscal years it compounded at +14.1% a year.
Context
- Selling, general & admin amounted to 51.2% of revenue in FY2025, up 0.2 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 14 analysts of $795.85M (+45.0%) for the fiscal year ending Dec 2026, a step up from the +12.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $159.2M-0.7% QoQ
- Last fiscal yearDec 2025
- $548.89M+12.4% YoY
- LTMSep 2026
- $646.09M+23.5% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 548.89M USD
- Year-over-year change
- +12.4%
- 4-year CAGR
- +8.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 548.89M | +12.4% |
| FY2024 | 2024-12-31 | 488.43M | +21.4% |
| FY2023 | 2023-12-31 | 402.47M | +9.0% |
| FY2022 | 2022-12-31 | 369.09M | -6.8% |
| FY2021 | 2021-12-31 | 396.03M | — |
Selling, General & Admin vs competitors
How ACAD compares with its peers on the latest reported figures
- ACAD's LTM Sep 2026 selling, general & admin of $646.09M is the 2nd highest of the 11 companies compared; the peer median is $35.95M.
- Its year-over-year change of +23.5% is the 6th highest of 10, against a peer median of +37.9%.
- Selling, general & admin amounts to 53.7% of revenue for ACAD, versus a peer median of 117.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $712.67M | +55.0% | +53.0% | 91.8% | |
| LTM Sep 2026 | $646.09M | +23.5% | +14.1% | 53.7% | |
| LTM Mar 2026 | $256.23M | +54.0% | +20.4% | 117.7% | |
| LTM Sep 2026 | $117.61M | +115.1% | -0.3% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $55.57M | -17.1% | +24.5% | — |
| LTM Mar 2026 | $37.63M | +164.2% | +95.7% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $34.27M | +37.9% | +181.0% | 171.4% |
| LTM Mar 2026 | $21.89M | -3.6% | +59.0% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $18.21M | — | +110.6% | — |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $17.4M | +18.2% | +41.6% | — |
| LTM Dec 2025 | $12.8M | +10.2% | +1.9% | — | |
| Peer median (excluding ACAD) | $35.95M | +37.9% | +47.3% | 117.7% | |
Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 484.15M | 517.24M | 726.44M | 957.8M | 1.07B |
| Cost of Revenue | 19.14M | 10.17M | 45.73M | 81.84M | 89M |
| Gross Profit | 465M | 507.07M | 680.71M | 875.96M | 982.51M |
| Gross Margin | 96.0% | 98.0% | 93.7% | 91.5% | 91.7% |
| Research & Development | 239.42M | 361.58M | 351.62M | 303.25M | 328.8M |
| Selling, General & Admin | 396.03M | 369.09M | 402.47M | 488.43M | 548.89M |
| Operating Expenses | 635.44M | 730.67M | 754.09M | 645.16M | 877.7M |
| Depreciation & Amortization | 3.34M | 2.03M | 5.55M | 15.88M | 11.76M |
| EBITDA | (164.18M) | (211.42M) | (45.48M) | 100.16M | 150.66M |
| EBITDA Margin | -33.9% | -40.9% | -6.3% | 10.5% | 14.1% |
| Operating Income | (170.44M) | (223.6M) | (73.38M) | 230.79M | 104.81M |
| Operating Margin | -35.2% | -43.2% | -10.1% | 24.1% | 9.8% |
| Interest Income | 591K | 6.61M | 17.23M | 25.46M | 31.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.92M | 10.15M | 22.34M | 27.28M | 34.09M |
| Income Before Tax | (167.52M) | (213.44M) | (51.04M) | 258.08M | 138.9M |
| Pre-Tax Margin | -34.6% | -41.3% | -7.0% | 26.9% | 13.0% |
| Income Tax Expense | 351K | 2.53M | 10.25M | 31.62M | (252.1M) |
| Net Income | (167.87M) | (215.98M) | (61.29M) | 226.45M | 391M |
| Net Margin | -34.7% | -41.8% | -8.4% | 23.6% | 36.5% |
| EPS (Basic) | (1.05) | (1.34) | (0.37) | 1.37 | 2.32 |
| EPS (Diluted) | (1.05) | (1.34) | (0.37) | 1.36 | 2.29 |
| Weighted Avg Shares | 160.49M | 161.68M | 163.82M | 165.72M | 169.34M |
| Weighted Avg Shares (Diluted) | 160.49M | 161.68M | 163.82M | 166.36M | 171.36M |
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
Intrinsic Alpha fair value
Locked
Current Price
$17.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.